OKYO Pharma Ltd. (OKYO) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.38

From 52W high−54.98%

Volume24113.00

Market cap$73.47M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.38

From 52W high

−54.98%

Volume

24113.00

Market cap

$73.47M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.7x

P/E (TTM)

—

RSI (14)

48.6

MomentumView details →

1D Return

−0.71%

YTD Return

−31.88%

SummaryUpdated Mar 1, 2026

OKYO Pharma Limited (NASDAQ:OKYO) is a preclinical biopharmaceutical company founded in 2007 and headquartered in London, United Kingdom. The company went public on May 17, 2022, and focuses on developing innovative therapeutics for patients suffering from inflammatory eye diseases and ocular pain. As a preclinical-stage company, OKYO Pharma has not yet generated revenue and is currently advancing its pipeline of ophthalmic treatments through research and development phases.

Ask drillr about OKYO Pharma Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

6.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−72.55%

ROA (TTM)

−42.67%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−99.25%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

−100.00%

EBITDA YoY

−43.15%

MomentumView details →

1D Return

−0.71%

YTD Return

−31.88%

1Y Return

−41.98%

RSI (14)

48.6

vs 50D SMA

−2.99%

vs 200D SMA

−15.26%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

2.43x

Quick Ratio

2.43x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.04

EPS Surprise

49.75%

Beats (12Q)

1/12

Next Q EPS Est

−$0.06

Avg Surprise (4Q)

8.48%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−13.66M

Op. CF (TTM)

−7.75M

Next earningsDec 2, 2026 →

Latest newsMore news →

OKYO Pharma Non-Executive Director John Brancaccio purchased 5,000 ordinary shares of the company on NASDAQ at $1.48 per share.88d ago

OKYO Pharma CEO Robert J. Dempsey purchased 15,000 ordinary shares on NASDAQ at $1.54 per share.88d ago

Similar companies

ProMIS Neurosciences, Inc.PMN Nutriband Inc.NTRB Acrivon Therapeutics, Inc. Common StockACRV Rani Therapeutics Holdings, Inc.RANI Telomir Pharmaceuticals, Inc. Common StockTELO Heron Therapeutics, Inc.HRTX Find similar companies →

Latest newsMore news →

OKYO Pharma Non-Executive Director John Brancaccio purchased 5,000 ordinary shares of the company on NASDAQ at $1.48 per share.88d ago OKYO Pharma CEO Robert J. Dempsey purchased 15,000 ordinary shares on NASDAQ at $1.54 per share.88d ago OKYO Pharma received positive FDA feedback from a Type D meeting supporting advancement of urcosimod into a Phase 3 trial for neuropathic corneal pain.103d ago